Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
QL Biopharm links monthly GLP-1 to incumbent-rivaling efficacy
The trial provides early evidence that the ultra-long-acting prospect can match the efficacy of weekly products from Eli Lilly and Novo Nordisk.
Nick Paul Taylor
Sep 18, 2025 7:20am
Novo seeks obesity refresh with $550M Replicate deal
Aug 28, 2025 7:00am
Viking hits stormy seas as phase 2 oral obesity data sink stock
Aug 19, 2025 9:44am
Response's ex-Sanofi asset hits goal in post-GLP-1 patients
Aug 13, 2025 9:14am
Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial
Aug 7, 2025 6:30am
Terns vows to stop funding metabolic disease trials beyond 2025
Aug 6, 2025 6:20am
